Cabaletta Bio Inc (CABA) concluded trading on Thursday at a closing price of $1.87, with 6.62 million shares of worth about $12.38 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -83.32% during that period and on November 21, 2024 the price saw a loss of about -17.26%. Currently the company’s common shares owned by public are about 47.82M shares, out of which, 41.36M shares are available for trading.
Stock saw a price change of -50.53% in past 5 days and over the past one month there was a price change of -53.60%. Year-to-date (YTD), CABA shares are showing a performance of -91.76% which decreased to -89.39% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.18 but also hit the highest price of $26.35 during that period. The average intraday trading volume for Cabaletta Bio Inc shares is 1.04 million. The stock is currently trading -49.55% below its 20-day simple moving average (SMA20), while that difference is down -54.10% for SMA50 and it goes to -81.65% lower than SMA200.
Cabaletta Bio Inc (NASDAQ: CABA) currently have 47.82M outstanding shares and institutions hold larger chunk of about 89.67% of that.
The stock has a current market capitalization of $91.40M and its 3Y-monthly beta is at 2.32. It has posted earnings per share of -$2.16 in the same period. It has Quick Ratio of 8.11 while making debt-to-equity ratio of 0.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CABA, volatility over the week remained 22.61% while standing at 11.77% over the month.
Stock’s fiscal year EPS is expected to drop by -38.81% while it is estimated to decrease by -13.78% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on October 10, 2024 offering a Buy rating for the stock and assigned a target price of $10 to it. Coverage by Jefferies stated Cabaletta Bio Inc (CABA) stock as a Buy in their note to investors on February 05, 2024, suggesting a price target of $36 for the stock. On November 29, 2023, William Blair Initiated their recommendations, while on October 24, 2023, Cantor Fitzgerald Initiated their ratings for the stock with a price target of $40. Stock get a Buy rating from Stifel on October 19, 2023.
